Search

An antibody test developed at MSK could shed light on the immune response to the COVID-19 virus.

… Tuesday, September 22, 2020 Summary A test developed by MSK researchers can detect three different antibodies to the COVID-19 virus. The test could help researchers clarify how someone fights off the virus, as well as who might be best protected if they are exposed a second time. Testing for antibodies

Blood pressure should be monitored closely and on an ongoing basis for several months after initiating ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL), according to our retrospective study.

… Wednesday, January 8, 2020 Blood pressure should be monitored closely and on an ongoing basis for several months after initiating ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL), according to our retrospective study published this month in JAMA Network Open . Hypertension is a

根据我们的回顾性研究，在慢性淋巴细胞白血病 (CLL) 患者开始接受伊鲁替尼治疗后，应密切监测其血压，并持续数月。

… Wednesday, January 8, 2020 根据我们本月发表在《美国医学会杂志网络公开》 (JAMA Network Open) 上的回顾性研究，在慢性淋巴细胞白血病 (CLL) 患者开始接受伊鲁替尼治疗后，应密切监测其血压，持续数月。 高血压是临床试验中接受伊鲁替尼治疗的 CLL 患者发生的常见不良事件。我们在非临床试验环境中研究了 CLL 患者中与伊鲁替尼相关的高血压的发展模式、管理策略和长期血管影响。  (1) 我们的结果显示，在接受伊鲁替尼治疗的 247 例 CLL 患者的整个队列中，包括存在和不存在高血压病史的患者，患者的血压均发生显著升高。 我们的结果显示，在接受伊鲁替尼治疗的

… Monday, March 24, 2025 Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and progress.  (1) Metastatic disease develops in about 50% of patients with surgically

Memorial Sloan Kettering Cancer Center (MSK) researchers presented the results of a randomized phase III trial at today’s press program for the European Society for Medical Oncology’s 2018 Congress in Munich, Germany. The results demonstrated that a combination of the immune checkpoint blocker avelumab (Bavencio®) and the tyrosine kinase inhibitor (TKI) axitinib (Inlyta®) can significantly improve progression-free survival (PFS) in people who have been previously untreated for advanced renal cell carcinoma (RCC).

… Sunday, October 21, 2018 Memorial Sloan Kettering Cancer Center (MSK) researchers presented the results of a randomized phase III trial at today’s press program for the European Society for Medical Oncology ’s 2018 Congress in Munich, Germany. The results demonstrated that a combination of the immune

Learn how MSK's world-class Head and Neck cancer specialists help people facing throat cancer, using the latest therapies and innovations.

… Thursday, September 4, 2025 Throat cancer is a form of head and neck cancer. It starts in the throat (known as the pharynx), which includes the tonsils, back of the tongue, voice box (larynx), and the vocal cords. Some of these areas can be seen when the mouth is wide open and others only by a camera

Three Gerstner Sloan Kettering students -- Marta Kovatcheva, Isabel Lam, and Elizabeth Wasmuth -- have been awarded grants that recognize their academic and research excellence.

… Friday, March 20, 2026 Marta Kovatcheva, a second-year student, has received a Natural Sciences and Engineering Research Council (NSERC) Postgraduate Scholarship (PGS). Since the agency’s inception in 1978, these scholarships have been providing financial support to high-caliber students engaged in master

For some patients with metastatic melanoma, a combination of two immunotherapies works better than either drug alone.

… Monday, April 3, 2017 Summary New study data presented at the 2017 AACR Annual Meeting showed that for some patients with metastatic melanoma , a combination of two immunotherapies works better than either drug alone. While some patients with metastatic melanoma benefit greatly from treatment with an

MSK highlights from the recent European Society for Medical Oncology (ESMO) Congress include promising findings on new lung, pancreatic, and colorectal cancer treatments and new insights for how molecular testing can guide personalized medicine.

… Tuesday, October 21, 2025 Researchers from Memorial Sloan Kettering Cancer Center (MSK) presented new studies related to a range of cancer types at the European Society for Medical Oncology (ESMO) Congress 2025, held October 17 to 21 in Berlin.   Highlights included the latest updates on three phase

MSK investigators are learning how cancer cells escape from the original tumor and hide out in the body. Their goal is to prevent metastatic tumors from forming.

… Friday, December 1, 2017 Summary Investigators at Memorial Sloan Kettering are conducting research to figure out how cancer cells are able to escape from the original tumor and hide out in the body. Their ultimate goal is to find ways to prevent metastatic tumors from forming. Cancer metastasis occurs